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Abstract
Introduction: Informed consent is a critical issue 
especially in conducting clinical trials that expose human 
life to medical or surgical interventions. It necessitates a 
long and complex process through which the participant is 
presented with all potential favorable and non-favorable 
consequences upon getting enrolled in the study.
Review: The process of taking informed consent is well-
understood in developed countries, with every effort 
taken to enhance and maintain the autonomy of patients 
and their right to make an informed choice of whether 
to participate or not. This may not be the case in the 
developing world. The information given to patients 
before the trial might not be properly developed and 
presented, an issue that can result in serious threat to the 
decision-making process. On the other hand, investigators 
should remember that enrolling people into a trial with 
no potential benefit for themselves cannot be considered 
ethical. In the current debate, we aim to address the issue 
of how respectfully and ethically clinical research trials 
can be done on human subjects and what we can do to 
enhance the practice in an ethical context. 
Conclusion: Development of a system through which we 
could warrant all rights of study participants in all cases 
around the world seems far from view. However, if we 
are in doubt about the ethics of a clinical trial, we can ask 
ourselves: “what would we do, if we were in the same 
position our patients are in now?” 
Keywords: Clinical trials; Developing World; Informed 
Consent
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Introduction
Informed and contented participation of people in 
clinical trials, even when adverse events are not likely, 
is of outmost relevance. It brings about a constructive 
relationship between the physician and the patient, 
potentially maximizing the safety of the study and 
enhancing favorable outcomes. It also minimizes side 
effects and feeling of coercion and disrespectfulness by 
the patients. When patients actively participate in a clinical 
trial, they feel more responsible to follow the instructions 
of their physicians. They would also have good feelings 
associated with helping to enhance their own health as 
well as medical science. However, information about the 
participation process given to patients before clinical trials 
is often not properly presented, an issue that can result in 
serious threat to the decision-making process. It may lead 
to distrust in the medical system and physicians which is 
very destructive for the patient-physician relationship.
The importance of taking informed consent from people 
participating in clinical trials is well-understood in 
developed countries, with every effort taken to enhance 
and maintain the autonomy of patients and their right to 
make an informed choice of whether to participate or not 
[1, 2]. Several legislations have been formed to protect 
people’s rights from potential abuse by pharmaceutical 
companies and/or investigators; although even in those 
countries, large fields still exist for modifications and 
enhancement. However, in the developing countries the 
land is still almost intact.
After a relatively long history of non-scientific approach 
to human life, the developing world has started to use 
scientific experimentations in the context of university-
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Because he did not understand some of the possible risks, 
he lost his son, as a result.
A proper informed consent necessitates appropriate 
communication prior to signing the document, through 
which the patient or a parent/legal representative having 
the custody of a child or a disabled person agrees to enter 
one into a clinical trial. This process, however, may not 
fully guarantee a complete understanding or a free right to 
decide. It may be done with lack of acknowledgement of 
some key information that may affect patients’ decision 
to participate [9]. For example, investigators are likely to 
be unwilling to share information on rare complications 
known to be associated with the research procedure. They 
often argue that giving this information is unnecessary 
due to their rare nature, and that sharing this information 
with patients increases their anxiety [10, 11]. However, it 
has been shown that patients want to know [12, 13]. 
Gain from the study
One of the ethical problems that occur in developing 
as well as developed countries is related to gain from 
the study. The investigator is supposed to be concerned 
about the efficacy of a treatment or preventive method 
in enhancing the health and quality of life of the study 
subjects themselves, besides prospective patients. People 
who participate in the study must be expected to benefit 
from the results of the study. So, enrolling people into a 
research with no potential benefit for themselves cannot 
be considered ethical. This is a critical issue that is easily 
disregarded in the developing countries. Investigators 
should not presume that giving a consent means that you 
can enter people into any clinical trial. 
Hidden coercion
Hidden coercion is another major concern on the ethics 
of the practice. Informed consent is a free and voluntary 
act which should be honestly and freely presented to the 
potential participants. People should not feel enforced to 
get involved into the study by their physicians, literally 
or non-literally. Investigators should not impose the 
feeling that if the patient does not admit to participate, 
he/she offends their physician; or he/she may not expect 
to receive full medical service, anymore. However, for 
encouraging the patients to participate, describing the 
importance of the research and its impact on treatment of 
the study subjects themselves, as well as the prospective 
patients is an ethical and necessary issue.  
Ethical issues in nephrology and kidney 
transplantation
With new medical procedures introduced into kidney 
medicine, the overall survival of people with renal 
failure has dramatically improved, and as a consequence, 
the number of end-stage renal disease (ESRD) patients 
has also increased. On the other hand, owing to more 
effective immunosuppressive agents employed in kidney 
transplant patients in the recent two decades, the outcome 
of these patients was significantly enhanced; and renal 
transplantation has become the treatment of choice for 
ESRD patients.
With the increasing numbers of ESRD patients and 
limited sources of kidney grafts from deceased donors, 
living donor renal transplantation has become more 
popular in clinical practice. One of the most tenacious 
ethical concerns over renal transplantation from living 
donors is that this procedure apparently endangers 
healthy individuals by exposing them to a potentially 
harmful procedure for saving another life. This dispute 
not only exists on transplantation from a non-related 
donor, it also applies to transplanting organs from related 
donors. However, while most ethicists are concerned with 
ethics of the procedure, few of them may consider the 
risk of unethical researches that may affect both kidney 
donors and recipients. Most kidney patients and living 
donors are at high risk for coercion to enter clinical trials, 
especially in the developing world where supportive 
organizations are not widely available. This issue will be 
of more relevance, when one considers living unrelated 
donors who are financially paid for donation. They might 
be at risk of being forced to enter research trials. 
Critical recommendations 
Knowing the problem and its relevance, herein we aim 
to present some suggestions to address the issue of 
making research endeavours more ethically acceptable 
in developing countries. For this purpose, the first 
step is to know and instate successful endeavours 
which have previously been used by the developed 
world. Establishment and/or empowering independent 
institutional review boards or ethics committees which 
can effectively supervise and control clinical trials 
might be the most important and fundamental work to 
be undertaken. These bodies are formally designated 
to review and approve research on humans. They are 
entrusted with protecting the rights, safety and wellbeing 
of subjects involved in a clinical trial, assuring the 
adequacy and safety of the informed consent and the 
clinical trial protocol and the adequacy of facilities. They 
typically include medical and non-medical members. 
On the other hand, reviewing histories for researches 
with unethical aspects previously performed in different 
countries as well as effective legal actions employed to 
address these cases can also help to resolve this problem. 
Besides all, to promote ethical aspects of research in the 
developing world we need international collaborative 
efforts. International scientific and ethics committees 
based educational models as a necessary requirement for 
faculty promotion. Our aim in this article is to address the 
issue of how respectfully and ethically clinical trials are 
performed on human subjects in the developing world; 
and what we can do to enhance the practice in an ethical 
context.
Review
Origins of the problem in the developing world
In the medical context, there are different ways for 
experimentation of which we can recall in vitro research, 
experimental research on animals, and clinical research 
on human subjects. Although ethical concerns exist on 
almost all types of the above mentioned, our debate 
focuses on clinical trials on human subjects. The two 
major problems that are frequently encountered in 
clinical trials in the developing world are: shortage of 
medical services and lack of supportive laws that protect 
patients against coercive efforts. This probably results in 
some investigators feeling free to enter their patients into 
clinical trials without respecting their feelings or rights. 
In one case, one of the authors recalls a colleague talking 
about how he had got consent from his patients to enter 
them into a non-favorable trial: “well, if they don’t want 
to participate, they can go to another hospital to get the 
service; I am their doctor, and I know what is good for 
everyone!” No doubt, this happens very frequently in 
these countries. This does not essentially mean that the 
research itself is non-ethical. Proper explanation often 
makes the study participants feel willing to participate, 
but the problem is that sometimes investigators do not 
feel they should make an explanation. If one observes 
the number of patients who have potentially refused to 
participate in different research trials in an area, he/she 
can have a better estimation of how many patients have 
been coerced to enter the trial, in that region.  
Informed consent document development and 
presentation
Case: In an Indian study on the natural behavior of 
precancerous cervical dysplasia [3], authors of the study 
entered 1158 women, untreated, with lesions of different 
stages who “had not given consent for taking treatment”, 
into a follow up from 1976 to 1988. According to debates 
by the investigators from the Institute of Cytology and 
Preventive Oncology in New Delhi, most of the study 
participants were illiterate. Here, the question is whether 
investigators described the potential effects of patients’ 
refusal to take the treatment properly; and despite that, 
they raised over one thousand individuals for inclusion 
into the study?
To get a clinical trial which has been done on human 
subjects published in a biomedical journals, these 
journals ask for confirmation that informed consent has 
been given by every study participant. You probably 
have to check a check-box stating that all people enrolled 
in your study have provided “informed” consent for 
inclusion. But how much are these consents informed, 
and how much are they consents, at all? Documents 
given to people to read and sign for inclusion into a 
study can contain controversial material, if they have 
been read at all. In one study, José Granero-Molina et 
al [4] found that linguistic communication difficulties, 
cultural clashes, asymmetry of communication between 
professionals and patients, assignment of rights on the 
part of patients, and overprotection of professionals and 
institutions affect the development of consent documents 
and the process of getting the informed consent. On the 
other hand, there is no consistency between ethicists 
on how to develop and present an informed consent 
document. In a study by Matthew Hotopf et al [5], six 
local ethical committees have been asked to argue on, 
and edit a consent document. Analysis showed that their 
arguments were very inconsistent and highly variable 
compared to each other. Gitangali et al [6] have reported 
that only less than one third of an in-patient population 
was likely to give informed consents to participate in 
a research trial. Moreover, Pope et al [7] showed that 
subjects who reported having understood the consent 
information letter had better recall of placebo/active drug 
comparator and better understanding of why placebo was 
used. These facts show the complexity and multi-factorial 
nature of the important issue of taking informed consent. 
We need to design an informed consent document which 
sufficiently addresses different concerns of ethicists, with 
the least possible threat to people rights.
Proper documentation and presentation of an 
informed consent
Case: Jesse Gelsinger was the first documented person 
publicly identified as having died in a clinical trial 
for gene therapy [8]. He was 18 years old at the time. 
Gelsinger suffered from ornithine transcarbamylase 
deficiency, a hepatic X-linked hereditary disease. He was 
enrolled into a clinical trial conducted by the University 
of Pennsylvania aiming at developing a treatment for 
infants born with the disease. Gelsinger was injected 
by an adenoviral vector carrying a normal gene, to test 
the safety of the procedure; but he died four days later, 
due to a massive immune response triggered by the viral 
vector used to transport the gene into his cells, leading 
to multiple organ failure and brain death. Although his 
father had given consent to participate in the trial, he had 
not been told enough about the risks of the procedure. 
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one into a clinical trial. This process, however, may not 
fully guarantee a complete understanding or a free right to 
decide. It may be done with lack of acknowledgement of 
some key information that may affect patients’ decision 
to participate [9]. For example, investigators are likely to 
be unwilling to share information on rare complications 
known to be associated with the research procedure. They 
often argue that giving this information is unnecessary 
due to their rare nature, and that sharing this information 
with patients increases their anxiety [10, 11]. However, it 
has been shown that patients want to know [12, 13]. 
Gain from the study
One of the ethical problems that occur in developing 
as well as developed countries is related to gain from 
the study. The investigator is supposed to be concerned 
about the efficacy of a treatment or preventive method 
in enhancing the health and quality of life of the study 
subjects themselves, besides prospective patients. People 
who participate in the study must be expected to benefit 
from the results of the study. So, enrolling people into a 
research with no potential benefit for themselves cannot 
be considered ethical. This is a critical issue that is easily 
disregarded in the developing countries. Investigators 
should not presume that giving a consent means that you 
can enter people into any clinical trial. 
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Hidden coercion is another major concern on the ethics 
of the practice. Informed consent is a free and voluntary 
act which should be honestly and freely presented to the 
potential participants. People should not feel enforced to 
get involved into the study by their physicians, literally 
or non-literally. Investigators should not impose the 
feeling that if the patient does not admit to participate, 
he/she offends their physician; or he/she may not expect 
to receive full medical service, anymore. However, for 
encouraging the patients to participate, describing the 
importance of the research and its impact on treatment of 
the study subjects themselves, as well as the prospective 
patients is an ethical and necessary issue.  
Ethical issues in nephrology and kidney 
transplantation
With new medical procedures introduced into kidney 
medicine, the overall survival of people with renal 
failure has dramatically improved, and as a consequence, 
the number of end-stage renal disease (ESRD) patients 
has also increased. On the other hand, owing to more 
effective immunosuppressive agents employed in kidney 
transplant patients in the recent two decades, the outcome 
of these patients was significantly enhanced; and renal 
transplantation has become the treatment of choice for 
ESRD patients.
With the increasing numbers of ESRD patients and 
limited sources of kidney grafts from deceased donors, 
living donor renal transplantation has become more 
popular in clinical practice. One of the most tenacious 
ethical concerns over renal transplantation from living 
donors is that this procedure apparently endangers 
healthy individuals by exposing them to a potentially 
harmful procedure for saving another life. This dispute 
not only exists on transplantation from a non-related 
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donors. However, while most ethicists are concerned with 
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donors and recipients. Most kidney patients and living 
donors are at high risk for coercion to enter clinical trials, 
especially in the developing world where supportive 
organizations are not widely available. This issue will be 
of more relevance, when one considers living unrelated 
donors who are financially paid for donation. They might 
be at risk of being forced to enter research trials. 
Critical recommendations 
Knowing the problem and its relevance, herein we aim 
to present some suggestions to address the issue of 
making research endeavours more ethically acceptable 
in developing countries. For this purpose, the first 
step is to know and instate successful endeavours 
which have previously been used by the developed 
world. Establishment and/or empowering independent 
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can effectively supervise and control clinical trials 
might be the most important and fundamental work to 
be undertaken. These bodies are formally designated 
to review and approve research on humans. They are 
entrusted with protecting the rights, safety and wellbeing 
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typically include medical and non-medical members. 
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developing world we need international collaborative 
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based educational models as a necessary requirement for 
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Origins of the problem in the developing world
In the medical context, there are different ways for 
experimentation of which we can recall in vitro research, 
experimental research on animals, and clinical research 
on human subjects. Although ethical concerns exist on 
almost all types of the above mentioned, our debate 
focuses on clinical trials on human subjects. The two 
major problems that are frequently encountered in 
clinical trials in the developing world are: shortage of 
medical services and lack of supportive laws that protect 
patients against coercive efforts. This probably results in 
some investigators feeling free to enter their patients into 
clinical trials without respecting their feelings or rights. 
In one case, one of the authors recalls a colleague talking 
about how he had got consent from his patients to enter 
them into a non-favorable trial: “well, if they don’t want 
to participate, they can go to another hospital to get the 
service; I am their doctor, and I know what is good for 
everyone!” No doubt, this happens very frequently in 
these countries. This does not essentially mean that the 
research itself is non-ethical. Proper explanation often 
makes the study participants feel willing to participate, 
but the problem is that sometimes investigators do not 
feel they should make an explanation. If one observes 
the number of patients who have potentially refused to 
participate in different research trials in an area, he/she 
can have a better estimation of how many patients have 
been coerced to enter the trial, in that region.  
Informed consent document development and 
presentation
Case: In an Indian study on the natural behavior of 
precancerous cervical dysplasia [3], authors of the study 
entered 1158 women, untreated, with lesions of different 
stages who “had not given consent for taking treatment”, 
into a follow up from 1976 to 1988. According to debates 
by the investigators from the Institute of Cytology and 
Preventive Oncology in New Delhi, most of the study 
participants were illiterate. Here, the question is whether 
investigators described the potential effects of patients’ 
refusal to take the treatment properly; and despite that, 
they raised over one thousand individuals for inclusion 
into the study?
To get a clinical trial which has been done on human 
subjects published in a biomedical journals, these 
journals ask for confirmation that informed consent has 
been given by every study participant. You probably 
have to check a check-box stating that all people enrolled 
in your study have provided “informed” consent for 
inclusion. But how much are these consents informed, 
and how much are they consents, at all? Documents 
given to people to read and sign for inclusion into a 
study can contain controversial material, if they have 
been read at all. In one study, José Granero-Molina et 
al [4] found that linguistic communication difficulties, 
cultural clashes, asymmetry of communication between 
professionals and patients, assignment of rights on the 
part of patients, and overprotection of professionals and 
institutions affect the development of consent documents 
and the process of getting the informed consent. On the 
other hand, there is no consistency between ethicists 
on how to develop and present an informed consent 
document. In a study by Matthew Hotopf et al [5], six 
local ethical committees have been asked to argue on, 
and edit a consent document. Analysis showed that their 
arguments were very inconsistent and highly variable 
compared to each other. Gitangali et al [6] have reported 
that only less than one third of an in-patient population 
was likely to give informed consents to participate in 
a research trial. Moreover, Pope et al [7] showed that 
subjects who reported having understood the consent 
information letter had better recall of placebo/active drug 
comparator and better understanding of why placebo was 
used. These facts show the complexity and multi-factorial 
nature of the important issue of taking informed consent. 
We need to design an informed consent document which 
sufficiently addresses different concerns of ethicists, with 
the least possible threat to people rights.
Proper documentation and presentation of an 
informed consent
Case: Jesse Gelsinger was the first documented person 
publicly identified as having died in a clinical trial 
for gene therapy [8]. He was 18 years old at the time. 
Gelsinger suffered from ornithine transcarbamylase 
deficiency, a hepatic X-linked hereditary disease. He was 
enrolled into a clinical trial conducted by the University 
of Pennsylvania aiming at developing a treatment for 
infants born with the disease. Gelsinger was injected 
by an adenoviral vector carrying a normal gene, to test 
the safety of the procedure; but he died four days later, 
due to a massive immune response triggered by the viral 
vector used to transport the gene into his cells, leading 
to multiple organ failure and brain death. Although his 
father had given consent to participate in the trial, he had 
not been told enough about the risks of the procedure. 
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must try to facilitate this process, and exert pressure on 
individuals and societies who refuse to respect ethics in 
their researches.  
Conclusion 
Despite all the issues mentioned above, development of a 
system through which we could warrant all rights of the 
study participants in all cases around the world seems far 
from view. However, as ethicists and investigators, we 
have the duty to do our best to maximize respectfulness 
to people’s right to decide on participation into clinical 
trials. In the context of developing world, we may have 
fewer instruments to apply ethical concerns on clinical 
trials performed in our countries, but the first step is 
probably to start from ourselves. If we are in doubt about 
the ethics of a clinical trial, we can ask ourselves: “what 
would we do, if we were in the same position our patients 
are in now?” 
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